NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- CALR exon 9 mutant peptide vaccine/Montanide ISA-51
A peptide vaccine consisting of a calreticulin (CALR) mutant peptide, CALRLong36, and montanide ISA 51 with potential antineoplastic activity. Upon vaccination, the CALR exon 9 mutant peptide vaccine may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL)-mediated response against tumor cells harboring mutations in exon 9 of the calreticulin gene. CALR, an endoplasmic reticulum chaperone protein that normally facilitates protein folding, immune response, and hematopoiesis, is often mutated in patients with chronic myeloproliferative neoplasms. In its mutant form, CALR is secreted into the plasma, where it binds to and activates the thrombopoietin receptor MPL and initiates downstream JAK/STAT signaling. Montanide ISA-51, also known as incomplete Freund's adjuvant or IFA, is a stabilized water-in-oil (w/o) emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: CALR exon 9 mutant peptide vaccine With Montanide ISA-51
CALRLong36 peptide vaccine/Montanide ISA-51